12:00 AM
Aug 08, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Kalbitor ecallantide: Phase II started

Dyax began a double-blind, placebo-controlled, U.S. Phase II trial to compare 10, 30 and 60 mg subcutaneous Kalbitor in combination with conventional therapy vs. conventional therapy alone in 176 patients. Dyax markets...

Read the full 140 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >